In Chicago this spring, oncologists presented findings that may reshape how doctors treat one of medicine's most stubborn adversaries: daraxonrasib, a daily oral pill that nearly doubled survival time in patients with advanced pancreatic cancer that had stopped responding to chemotherapy.
Pancreatic cancer has long been a grim diagnosis. Unlike breast or lung cancers, where decades of research have extended survival to five years or beyond, progress against pancreatic cancer has moved at what specialists call "a snail's pace." Three decades ago, median survival for advanced cases hovered around six months; even with aggressive multi-drug chemotherapy today, it barely reaches twelve months. The five-year survival rate stands at just 13 percent, and around 67,000 Americans are expected to receive a pancreatic cancer diagnosis this year, with more than 52,000 projected to die from the disease. The tragedy is compounded by late detection—symptoms remain vague in early stages, and the disease often spreads to other organs before diagnosis.
This context makes the new findings, presented at the American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine, genuinely extraordinary. In a phase III clinical trial involving approximately 500 patients with metastatic pancreatic cancer whose disease had worsened despite prior treatment, median overall survival reached 13.2 months for those taking daraxonrasib, compared to just 6.7 months for those receiving standard chemotherapy. Patients on the new drug not only lived longer—they reported better quality of life and lower pain levels, with substantial tumour shrinkage observed across many participants.
The mechanism behind this breakthrough addresses a problem scientists had deemed nearly unsolvable. More than 90 percent of pancreatic cancers carry mutations in the KRAS gene, which drives uncontrolled tumour growth. For decades, KRAS was dismissed as "undruggable"—a technical term that reflected genuine despair in the oncology community. Daraxonrasib overcomes this by using a molecular binding mechanism that attaches to multiple KRAS mutation subtypes and blocks their cancer-promoting activity, marking a watershed moment in targeted therapy.
Dr. Deepak Sundriyal of AIIMS, Rishikesh, captured the significance plainly: "For patients whose disease has already spread and stops responding to the first treatment, the outlook is usually poor. Any therapy that significantly extends survival while maintaining quality of life is an important development." Dr. Anant Ramaswamy of Tata Memorial Centre in Mumbai echoed the sentiment, noting that pancreatic cancer has long bred "a fair degree of nihilism in the oncology community." When an oral tablet nearly doubles survival in chemotherapy-resistant patients, he says, "there is reason to look for a silver lining."
The practical advantages compound the promise. Daraxonrasib is an oral medication—patients take it daily at home, not intravenously in hospital infusions. Many trial participants were still receiving the drug when data were analysed, suggesting that survival benefits could increase further with extended follow-up. Researchers also noted that patients remained on treatment significantly longer than those assigned to chemotherapy, a sign of both efficacy and tolerability.
For oncologists and patients facing metastatic pancreatic cancer—a disease that has long offered few second chances—daraxonrasib represents something rare: a genuinely new tool, backed by data, that works.